ARAsad Gul Rao

Asad Gul Rao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Asad Gul Rao has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Single-stage surgical management versus conventional two-stage management for pediatric choledocholithiasis: A systematic review and meta-analysis

    by Muhammad Taha Nasim, Muhammad Tabish Nasim, Asad G. Rao, Javeria Javed, Shruthi Athavan, Daniel Tahan, Asad Saulat Fatimi, Humza Thobani, Anam N. Ehsan, Bilal Iqbal, et al.

  • Association of surgical antibiotic prophylaxis with postoperative outcomes following pediatric gastrostomy tube placement: A propensity score overlap weighted analysis

    by Muhammad Osama Khan, Humza Thobani, Sharjeel Ahmad, Bilal Iqbal, Daniel Tahan, Anam Noor Ehsan, Asad Gul Rao, Timothy Tirrell, Saleem Islam, Faraz A. Khan


  • Comparing Palliative Approaches for GOO in Locally Advanced Pancreatic Cancer: A Systematic Review and Meta‐Analysis

    by Asad Gul Rao, Muhammad Ahmad Nadeem, Abdul Rafeh Awan, Chase J. Wehrle, Abby Gross, Antonio Giuseppucci, Beren Berber, Syed Mohiuddin, Tyler Stevens, Hassan Siddiki, et al.

    Gastric outlet obstruction (GOO) in locally advanced pancreatic cancer (LAPC) can be managed with endoscopic duodenal stenting (EDS), gastrojejunostomy (GJ), or EUS‐guided gastroenterostomy (EUS‐GE). In our meta‐analysis of LAPC patients, EDS enabled quicker recovery and chemotherapy but had higher re‐intervention rates, while GJ offered greater durability. Our systematic review showed EUS‐GE had high success and low re‐intervention in malignant GOO, though LAPC‐specific data were lacking. Further comparative studies are needed to guide individualized treatment.


  • Open Access

    Role of antibiotic prophylaxis in liver transplant patients undergoing endoscopic retrograde cholangiopancreatography: a systematic review and meta-analysis

    by Muhammad Ahmad Nadeem, Abdul Rafeh Awan, Asad Gul Rao, Meher Ayyazuddin, Umm E. Salma Shabbar Banatwala, Sobia Laique, Puneet Bansal, Shilpa Junna, Hassan Siddiki, Christine Koval, et al.


  • Open Access

    Trends and disparities in mortality due to hypertensive disease and coexisting obesity in the USA: 1999–2023

    by Asad Gul Rao, Amna Parvez, Sufyan Shahid, Neha Pervez, Jamal S. Rana, Marat Fudim, Muhammad Shahzeb Khan

    Background: Hypertensive disease and obesity frequently coexist and synergistically increase the risk of cardiovascular morbidity and mortality in the USA. Despite this intersection, national trends and disparities in mortality attributable to both conditions remain underexplored. Methods: We conducted a retrospective analysis using the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research Multiple Cause of Death database. Hypertensive disease-related deaths with co-listed obesity were extracted for US adults between 1999 and 2023. Age-adjusted mortality rates (AAMRs) were calculated, and Joinpoint regression was used to estimate annual percentage changes (APCs) and identify significant trends. Results: A total of 412,767 deaths were attributed to hypertensive disease and coexisting obesity from 1999 and 2023. The AAMRs rose nearly tenfold, from 1.3 per 100,000 in 1999 to 13.23 in 2023. While mortality rates increased overtime for both sexes, men consistently exhibited higher rates than women (AAPC: 10.38 vs. 8.15). Older adults (AAMR: 32.63) had the highest mortality, followed by middle-aged (5.56) and young adults (0.71), though young adults saw the steepest relative rise (AAPC: 9.63). Non-Hispanic (NH) Black individuals had the highest mortality (AAPC: 7.78), followed by NH American Indian/Alaska Native (8.76), NH White (9.90), Hispanic (6.48) and NH Asian/Pacific Islander populations (6.51). Geographic disparities widened over time. The South and Midwest bore the heaviest regional burden, while urban–rural analyses showed a higher and quicker rise in mortality in non-metropolitan areas (AAPC: 12.13 vs. 10.73 in metro areas). Conclusion: Mortality due to hypertensive disease with coexisting obesity has escalated sharply across USA over the past 2 decades. These results highlight the need for further investigation into the factors contributing to the observed disparities and trends. Graphical Mortality due to hypertensive disease and coexisting obesity in the USA: 1999–2023


  • Open Access

    Trends and Disparities in Mortality due to Diabetes Mellitus and Sepsis in the US Adults: 1999–2023

    by Asad Gul Rao, Sufyan Shahid, Neha Pervez, Ramsha Pervez, Raheel Ahmed

    Background: Diabetes mellitus (DM) increases susceptibility to infection and worsens outcomes in sepsis, a leading cause of preventable death. However, population‐level trends in sepsis‐related mortality among diabetic individuals in the United States (US) remain poorly characterised, especially in the context of the COVID‐19 pandemic. This study evaluates national patterns, temporal shifts, and demographic disparities in sepsis‐related mortality in diabetic patients from 1999 to 2023. Methods: We conducted a retrospective analysis using the Centers for Disease Control and Prevention Wide‐ranging Online Data for Epidemiologic Research (CDC WONDER) Multiple Cause of Death database. Sepsis‐related deaths with co‐listed DM were extracted for US adults between 1999 and 2023. Age‐adjusted mortality rates (AAMRs) were calculated and Joinpoint regression was used to estimate annual percentage changes (APCs) and identify significant trends. Results: A total of 483,207 sepsis‐related deaths occurred in individuals with DM during the study period. AAMRs declined significantly from 1999 to 2018 (APC: −1.22; p < 0.001), reversed sharply from 2018 to 2021 (APC: +18.14; p = 0.01), and declined again through 2023 (APC: −12.25; p < 0.001). Mortality was highest among older adults (AAMR: 32.63), males (9.72 vs. 7.80 in females), and non‐Hispanic Black and American Indian/Alaska Native populations (AAMRs: 17.94 and 17.92, respectively). Hispanic populations showed the steepest pandemic‐era increase (APC: +22.49) and subsequent decline (APC: −20.43). Rural areas consistently had higher AAMRs than urban areas (8.77 vs. 8.27), with sharper increases during the pandemic. State‐level disparities widened dramatically from 2021 to 2023, and regionally, the South and Midwest exhibited the highest and most persistent mortality burdens. Conclusion: Sepsis‐related mortality in diabetic individuals in the US has undergone dynamic shifts over the past 25 years, punctuated by COVID‐19 era surges and shaped by deep‐rooted demographic, geographic, and structural inequities. These findings warrant integrated diabetes‐infection care models, early sepsis recognition, and equity‐driven interventions to reduce mortality.


  • Open Access

    Comparative Effectiveness of Epidural Analgesia and Intravenous Lidocaine for Postoperative Pain in Major Abdominal Surgery: A Systematic Review and Meta‐Analysis

    by Mohammad Jawwad, Dawar Nadeem Aslam Dar, Rana Faheem Ullah Khan, Aizaz Chaudhry, Faraz Arkam, Asad Gul Rao, Yusra Mir, Mohammad Maheer Mubashir, Aqsa Mir, Haider Imran, et al.

    Background: Pain management is an integral part of recovery after major abdominal surgeries. Traditionally, epidural analgesia is used for postoperative pain management in major abdominal surgeries. However, intravenous lidocaine has recently been proven to be a good alternative. However, there is very limited evidence comparing their efficacy in major abdominal surgery. The aim of this review is to compare the effectiveness of epidural analgesia with intravenous lidocaine in reducing pain and opioid consumption following major abdominal surgery. Methods: We searched PubMed and Cochrane Library from inception to May 2024 to identify studies that match our topic. We performed all statistical analyses using RevMan. The primary outcome was pain scores. The other outcomes were opioid requirements, postoperative nausea and vomiting, hospital stay duration, and time to pass flatus. Results: Seven studies (six randomized clinical trials and one observational study; n = 643) were included. Our results suggest that epidural bupivacaine significantly reduced pain scores during the first 24 h postoperatively as compared with the patients who received intravenous lidocaine (Std. mean difference: −0.23; 95% confidence interval [CI]: −0.40, −0.06; and p = 0.008). There was no difference at 48 h (Std. mean difference: −0.09; 95% CI: −0.27, 0.08; and p = 0.028) and 72 h intervals (Std. mean difference: −0.08; 95% CI: −0.25, 0.09; and p = 0.037). Conclusion: Our study shows that epidural analgesia, particularly epidural bupivacaine, provides superior pain relief as compared to intravenous lidocaine during the first 24 h postoperatively. However, there was heterogeneity among studies. Thus, in future, large standardized randomized controlled trials are required.


  • Open Access

    Entangled: Rapunzel syndrome with postoperative intussusception

    by Zoha Shahzad, Osama Ijaz, Umar Akram, Neha Pervez, Asad Gul Rao, Abdulqadir J Nashwan

    We present a case of a 7-year-old girl with Rapunzel syndrome, a rare complication of trichobezoar, initially presenting with nonspecific symptoms. Diagnostic challenges led to delayed intervention. Surgical removal of the trichobezoar was successful, but postoperative complications included jejunojejunal intussusception, highlighting the necessity for vigilant follow-up and comprehensive psychiatric evaluation. The emergence of intussusception emphasizes the profound impact of underlying psychiatric disorders, such as trichotillomania and trichophagia, which contribute to trichobezoar formation. These conditions necessitate ongoing psychiatric management to address behavioral factors that predispose to recurrent bezoar formation and associated gastrointestinal complications. Effective follow-up strategies should encompass immediate postoperative care and long-term psychiatric support to optimize patient outcomes and minimize the risk of recurrent intussusception.